Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Co.'s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. Co.'s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. We show 53 historical shares outstanding datapoints in our GALT shares outstanding history coverage, used to compute GALT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GALT market cap history over the course of time is important for investors
interested in comparing GALT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GALT versus a peer is one thing; comparing
GALT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GALT can fluctuate over the course of history.
With this page we aim to empower investors researching GALT by allowing them to research the GALT market cap history. |
Free GALT Email Alerts:
Video: The Importance of Market Cap
